The Clinical Significance of PR, ER, NF-κB, and TNF-α in Breast Cancer

Table 5

The relationship between these four parameters and clinicopathological features (𝑛=112).

Parameters	PR (𝑛)		𝜒^2	𝑃	ER (𝑛)		𝜒^2	𝑃	TNF-𝛼 (𝑛)		𝜒^2	𝑃	NF-κB (𝑛)		𝜒^2	𝑃
	+	−			+	−			+	−			+	−
Age (y)
<50	39	17	0.36	0.55	40	16	1.22	0.27	54	2	1.37	0.24	4	12	1.85	0.17
≥50	36	20			45	11			51	5			5	6
Histologic subtype
DC	65	32	3.77	0.44	76	21	5.22	0.27	91	6	3.13	0.54	8	14	2.18	0.70
ILC	3	3			4	2			6	0			4	2
MA	2	2			2	2			3	1			3	1
IC	4	0			3	1			4	0			3	1
LC in situ	1	0			0	1			1	0			1	0
TNM stages
I-II	36	30	11.20	<0.01	45	21	7.57	<0.01	59	7	5.20	0.02	4	17	11.18	<0.01
III-IV	39	7			40	6			46	0			4	1
Tumor grade
I-II	39	36	22.98	<0.01	50	25	10.56	<0.01	68	7	3.68	0.06	5	17	7.32	<0.01
III	36	1			35	2			37	0			3	1
Tumor size
<5 cm	50	27	0.46	0.50	57	20	0.47	0.49	75	2	5.61	0.01	6	17	6.59	0.01
≥5 cm	25	10			28	7			30	5			3	1
Lymph node metastasis
Yes	50	10	15.65	<0.01	55	5	17.57	<0.01	60	0	8.62	<0.01		2	15.55	<0.01
No	25	27			30	22			45	7			3	16
Age at menarche (y)
<15	55	21	3.12	0.08	58	18	0.02	0.88	70	6	1.09	0.30	6	12	0.01	0.91
≥15	20	16			27	9			35	1			3	6
Menopause
Yes	44	17	1.62	0.20	45	16	0.33	0.57	55	6	2.94	0.09	5	10	0.01	0.92
No	31	20			40	11			50	1			4	8
Number of pregnancies
<4	50	25	0.01	0.92	60	15	2.09	0.15	70	5	0.07	0.80	6	11	0.33	0.56
≥4	25	12			25	12			35	2			3	7
Number of deliveries
<3	61	34	2.15	0.14	75	20	3.19	0.07	90	5	1.04	0.31	7	16	0.28	0.60
≥3	14	3			10	7			15	2			1	2
Family history
Yes	16	5	1.00	0.32	14	7	1.20	0.27	20	1	0.10	0.76	1	6	3.00	0.08
No	59	32			71	20			85	6			7	12

PR: progesterone receptor; ER: estrogen receptor; NF-κB: nuclear factor-κB; TNF-𝛼: tumor necrosis factor-𝛼. PR: progesterone receptor; ER: estrogen receptor; NF-κB: nuclear factor-κB; TNF-𝛼: tumor necrosis factor-𝛼; DC: ductal carcinoma; ILC: invasive lobular carcinoma; MA: mucinous adenocarcinoma; IC: intraductal carcinoma; IC in situ: lobular carcinoma in situ.